1-3 of 3
Pamela L. Walker, RN
Close
Sort by
Journal Articles

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Peter McLaughlin, MD, Luis Fayad, MD, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Anas Younes, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Pamela L. Walker, RN, Maria A. Rodriguez, MD, Larry Kwak, MD, PhD, Barbara Pro, MD
Journal: Blood
Blood (2005) 106 (11): 3349.
https://doi.org/10.1182/blood.V106.11.3349.3349
Published: 2005
Journal Articles

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Maria Rodriguez, MD, Andre Goy, MD, Jorge Romaguera, MD, Pamela L. Walker, RN, Anas Younes, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Luis Fayad, MD
Journal: Blood
Blood (2005) 106 (11): 3350.
https://doi.org/10.1182/blood.V106.11.3350.3350
Published: 2005
Journal Articles

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick B. Hagemeister, MD, Dan Jones, MD, PhD, Barry Samuels, MD, Maria A. Rodriguez, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Pamela L. Walker, RN, Larry Kwak, MD, PhD, Luis Fayad, MD
Journal: Blood
Blood (2004) 104 (11): 2641.
https://doi.org/10.1182/blood.V104.11.2641.2641
Published: 2004